These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 6572561)
21. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model. Hagenbeek A; Martens AC Cancer Res; 1983 Jan; 43(1):408-12. PubMed ID: 6336603 [TBL] [Abstract][Full Text] [Related]
23. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells. Richel DJ; Colly LP; Arkesteijn GJ; Arentsen-Honders MW; Kerster MG; ter Riet PM; Willemze R Cancer Res; 1990 Oct; 50(20):6515-9. PubMed ID: 2208110 [TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429 [TBL] [Abstract][Full Text] [Related]
25. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment. Danhauser LL; Rustum YM Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756 [TBL] [Abstract][Full Text] [Related]
26. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Shiozawa K; Nakanishi T; Tan M; Fang HB; Wang WC; Edelman MJ; Carlton D; Gojo I; Sausville EA; Ross DD Clin Cancer Res; 2009 Mar; 15(5):1698-707. PubMed ID: 19223502 [TBL] [Abstract][Full Text] [Related]
27. Diamine oxidase as a plasma marker of rat intestinal mucosal injury and regeneration after administration of 1-beta-D-arabinofuranosylcytosine. Luk GD; Vaughan WP; Burke PJ; Baylin SB Cancer Res; 1981 Jun; 41(6):2334-7. PubMed ID: 6786736 [TBL] [Abstract][Full Text] [Related]
28. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970 [TBL] [Abstract][Full Text] [Related]
29. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin. Ritch PS; Occhipinti SJ; Cunningham RE; Shackney SE Cancer Res; 1981 Oct; 41(10):3881-4. PubMed ID: 7284997 [TBL] [Abstract][Full Text] [Related]
30. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M; Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916 [TBL] [Abstract][Full Text] [Related]
31. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML). Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932 [TBL] [Abstract][Full Text] [Related]
32. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808 [TBL] [Abstract][Full Text] [Related]
33. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia]. Ohshima A; Yoshida K; Sato T; Miyazaki S; Yanagisawa M; Nakayama Y; Takahashi T; Mamiya S; Fukusima Y; Miura AB Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405 [TBL] [Abstract][Full Text] [Related]
34. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
35. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631 [TBL] [Abstract][Full Text] [Related]
36. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice. Berdel WE; Okamoto S; Danhauser-Riedl S; Hong CI; Winton EF; West CR; Rastetter J; Vogler WR Exp Hematol; 1989 May; 17(4):364-7. PubMed ID: 2707318 [TBL] [Abstract][Full Text] [Related]
38. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Capizzi RL; White JC; Powell BL; Perrino F Semin Hematol; 1991 Jul; 28(3 Suppl 4):54-69. PubMed ID: 1780754 [TBL] [Abstract][Full Text] [Related]
39. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358 [TBL] [Abstract][Full Text] [Related]
40. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture. Fountzilas G; Inoue S; Ohnuma T Leukemia; 1990 May; 4(5):321-4. PubMed ID: 2388478 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]